142 related articles for article (PubMed ID: 9099452)
1. Toxicokinetic evaluation of a selegiline transdermal system in the dog.
Barrett JS; DiSanto AR; Thomford PJ; Larsen EM; Palazzolo MJ; Morales RJ
Biopharm Drug Dispos; 1997 Mar; 18(2):165-84. PubMed ID: 9099452
[TBL] [Abstract][Full Text] [Related]
2. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration.
Rohatagi S; Barrett JS; DeWitt KE; Morales RJ
Biopharm Drug Dispos; 1997 Oct; 18(7):567-84. PubMed ID: 9330778
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system.
Rohatagi S; Barrett JS; DeWitt KE; Lessard D; Morales RJ
Biopharm Drug Dispos; 1997 Nov; 18(8):665-80. PubMed ID: 9373724
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Dosing Regimen and Food on the Bioavailability of the Extensively Metabolized, Highly Variable Drug Eldepryl(®) (Selegiline Hydrochloride).
Barrett JS; Rohatagi S; DeWitt KE; Morales RJ; DiSanto AR
Am J Ther; 1996 Apr; 3(4):298-313. PubMed ID: 11862265
[TBL] [Abstract][Full Text] [Related]
5. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.
Laine K; Anttila M; Huupponen R; Mäki-Ikola O; Heinonen E
Clin Neuropharmacol; 2000; 23(1):22-7. PubMed ID: 10682227
[TBL] [Abstract][Full Text] [Related]
7. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.
Mawhinney M; Cole D; Azzaro AJ
J Pharm Pharmacol; 2003 Jan; 55(1):27-34. PubMed ID: 12625864
[TBL] [Abstract][Full Text] [Related]
8. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of a selegiline transdermal system relative to single-dose oral administration in the elderly.
Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; DiSanto AR
Am J Ther; 1996 Oct; 3(10):688-98. PubMed ID: 11862224
[TBL] [Abstract][Full Text] [Related]
10. Transdermal selegiline: the new generation of monoamine oxidase inhibitors.
Patkar AA; Pae CU; Masand PS
CNS Spectr; 2006 May; 11(5):363-75. PubMed ID: 16641841
[TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of buccoadhesive tablet for selegiline hydrochloride based on thiolated polycarbophil.
Wasnik MN; Godse RD; Nair HA
Drug Dev Ind Pharm; 2014 May; 40(5):632-8. PubMed ID: 24517570
[TBL] [Abstract][Full Text] [Related]
12. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
Mahmood I
Clin Pharmacokinet; 1997 Aug; 33(2):91-102. PubMed ID: 9260033
[TBL] [Abstract][Full Text] [Related]
14. Selegiline percutaneous absorption in various species and metabolism by human skin.
Rohatagi S; Barrett JS; McDonald LJ; Morris EM; Darnow J; DiSanto AR
Pharm Res; 1997 Jan; 14(1):50-5. PubMed ID: 9034220
[TBL] [Abstract][Full Text] [Related]
15. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
[TBL] [Abstract][Full Text] [Related]
17. Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.
Barrett JS; Szego P; Rohatagi S; Morales RJ; De Witt KE; Rajewski G; Ireland J
Pharm Res; 1996 Oct; 13(10):1535-40. PubMed ID: 8899847
[TBL] [Abstract][Full Text] [Related]
18. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.
Palovaara S; Anttila M; Nyman L; Laine K
Eur J Clin Pharmacol; 2002 Jul; 58(4):259-63. PubMed ID: 12136372
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.
Harris DS; Everhart T; Jacob P; Lin E; Mendelson JE; Jones RT
BMC Clin Pharmacol; 2009 Aug; 9():13. PubMed ID: 19646280
[TBL] [Abstract][Full Text] [Related]
20. Selegiline transdermal system: current awareness and promise.
Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
